|
|
|
29.04.25 - 17:51
|
Median Technologies Reports Full-year 2024 Financial Results (Business Wire)
|
|
|
Returns to FY revenue growth in 2024 (+3.3%), with acceleration in H2 (+10.2%)
Slight decrease in operating loss, from €23.1 million in 2023 to €22.5 million in 2024
Operational improvements in H2 2024, to reduce cash burn and improve iCRO profitability, delivering full impact in 2025
Q1 2025 revenues up 11% over Q1 2024, order backlog at all-time high, €74.8 million as of March 31, 2025
eyonis™ Lung Cancer Screening (LCS) pivotal REALITY and RELIVE studies met all key endpoints
U.S. FDA 510(k) filing in May 2025, CE marking filing expected in June.
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today reported its 2024 consolidated...
|
|
|
24.04.25 - 17:51
|
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements (Business Wire)
|
|
|
€6.0 million in Q1 2025 revenues, up 11% over Q1 2024
€74.8 million all-time high order backlog as of March 31, 2025
eyonis™ LCS pivotal RELIVE study met all key endpoints
U.S. FDA 510(k) filing on track for May 2025, filing for CE marking expected in June 2025.
eyonis™ LCS commercial launches as soon as year-end 2025 in U.S. and H1 2026 in Europe, pending regulatory approvals
Cash and cash equivalents at €8.8 million as of March 31, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, releases today its Q1 2025 key financial indicators (unaudited) and provides an update on Q1 operational achievements.
Fredrik Brag, CEO and Founde...
|
|
|
03.03.25 - 17:51
|
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders′ Extraordinary General Meeting on March 20, 2025 (Business Wire)
|
|
|
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) are invited to participate in the Shareholders' Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris.
All useful information relating to this Shareholders' General Meeting is regularly updated on Median Technologies' website.
Shareholders may exercise their voting rights before the holding of the Shareholders' General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise of the right to vote are specified in the notice of the Shareholders' General Meeting, available here on Median's website
The preliminary notice of the Shareholders' General Meeting has been published in the BALO (Bulletin des annonces légales obligatoires) on February 10, 2025, and has not been s...
|
|
|
11.02.25 - 17:51
|
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025 (Business Wire)
|
|
|
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares
18,631,386
Number of real voting rights* (excluding treasury shares**)
18,567,201
Theoretical number of voting rights* (including treasury shares**)
18,608,186
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF's General Regulations
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of nove...
|
|
|
05.02.25 - 17:48
|
Median Technologies Gives Update on Drawdowns of the Iris Equity Line (Business Wire)
|
|
|
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-based image analyses and imaging services for oncology drug developers, announced that, on January 23, 2025, the Company signed a financing agreement with Iris in the form of bonds redeemable in shares for a maximum amount of €10 million. On January 24, 2025, Iris subscribed to an initial tranche of 1,600 redeemable bonds of a nominal value of €4 million.
The Company will have the right to suspend and reactivate the drawdowns of the tranches without penalty. The key terms and conditions of the financing facility are as follows:
A single tranche of 4,000 warrants, subscribed by Iris Capital, each warrant entitling its holder to subscribe to a bond redeemable in shares,
Iris Capital has committe...
|
|
|
24.01.25 - 08:06
|
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU (Business Wire)
|
|
|
Repayment of 2020 EIB loan to be rescheduled to October 2025 from April
New €37.5 million 2025 EIB loan under appraisal, final authorization stage
New up to €10 million equity line completed with IRIS to enable 2025 EIB loan
eyonis™ LCS RELIVE pivotal study data in Q1 2025
eyonis™ LCS U.S. FDA 510(k) and EU CE mark filings on track for Q2 2025
US commercial launch on track for Q4 2025 in U.S.
Active discussions ongoing with leading U.S. AI diagnostics commercial organizations for potential eyonis™ LCS marketing deal
Operational improvements enhancing profitability of iCRO business
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers, today announces the ...
|
|
|
14.01.25 - 17:48
|
Median Technologies: Financial Communications Schedule for the First Half of 2025 (Business Wire)
|
|
|
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results:
Publication
Date
2024 results
April 29, 2025*
*Distribution after the close of trading
About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan schem...
|
|
|
08.01.25 - 17:48
|
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024 (Business Wire)
|
|
|
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF's General Regulations.SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares
18,516,983
Number of real voting rights* (excluding treasury shares**)
18,463,224
Theoretical number of voting rights* (including treasury shares**)
18,493,783
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF's General Regulations
About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The Fr...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
